82 related articles for article (PubMed ID: 8552578)
1. Brief report: detection of high-molecular-weight cytokeratins in neoplastic and non-neoplastic thyroid tumors using microwave antigen retrieval.
Raphael SJ; Apel RL; Asa SL
Mod Pathol; 1995 Oct; 8(8):870-2. PubMed ID: 8552578
[TBL] [Abstract][Full Text] [Related]
2. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
3. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
4. CA 50 and CA 19-9 antigen expression in normal, hyperplastic, and neoplastic thyroid tissue.
Vierbuchen M; Schröder S; Uhlenbruck G; Ortmann M; Fischer R
Lab Invest; 1989 May; 60(5):726-32. PubMed ID: 2716285
[TBL] [Abstract][Full Text] [Related]
5. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
Ziadi S; Trimeche M; Zermani R; Elmay A; Baltagi-Ben Jilani S
Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
[TBL] [Abstract][Full Text] [Related]
7. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
[TBL] [Abstract][Full Text] [Related]
10. [HBME-1 immunostaining in thyroid pathology].
Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
[TBL] [Abstract][Full Text] [Related]
11. The significance of the grooved nucleus in thyroid lesions.
Scopa CD; Melachrinou M; Saradopoulou C; Merino MJ
Mod Pathol; 1993 Nov; 6(6):691-4. PubMed ID: 8302810
[TBL] [Abstract][Full Text] [Related]
12. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
Erickson LA; Yousef OM; Jin L; Lohse CM; Pankratz VS; Lloyd RV
Mod Pathol; 2000 Sep; 13(9):1014-9. PubMed ID: 11007042
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
14. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin expression profiles in thyroid carcinomas.
Lam KY; Lui MC; Lo CY
Eur J Surg Oncol; 2001 Nov; 27(7):631-5. PubMed ID: 11669590
[TBL] [Abstract][Full Text] [Related]
16. Pathologic features of Hashimoto's-associated papillary thyroid carcinomas.
Di Pasquale M; Rothstein JL; Palazzo JP
Hum Pathol; 2001 Jan; 32(1):24-30. PubMed ID: 11172291
[TBL] [Abstract][Full Text] [Related]
17. Objective differential classification of thyroid lesions by nuclear quantitative assessment.
Artacho-Pérula E; Roldán-Villalobos R; Blanco-García F; Blanco-Rodríguez A
Histol Histopathol; 1997 Apr; 12(2):425-31. PubMed ID: 9151131
[TBL] [Abstract][Full Text] [Related]
18. Epithelial membrane antigen and S-100 protein expression in benign and malignant papillary thyroid neoplasms.
Kilicarslan B; Pesterelli EH; Oren N; Sargin FC; Karpuzoglu G
Adv Clin Path; 2000 Oct; 4(4):155-8. PubMed ID: 11436147
[TBL] [Abstract][Full Text] [Related]
19. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions.
Mitselou A; Vougiouklakis TG; Peschos D; Dallas P; Boumba VA; Agnantis NJ
Anticancer Res; 2002; 22(3):1777-80. PubMed ID: 12168868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
